| Demographic | pSS (n=55) | SLE/SS (n=15) | Significance |
|---|---|---|---|
| Sex n (female/male %) | 55 (100/0) | 15 (100/0) | |
| Ethnicity n (C/A/MN/O) | 43/6/3/3 | 9/1/5/0 | P=0.4571 |
| Age mean (range) | 58 (28–84) | 56 (25–78) | P=0.5923 |
| Disease duration mean (range) | 12 (2–34) | 23 (3–40) | P=**0.005 |
| Anti-Ro+ % (n) | 76 (42) | 73 (11) | P=0.7273 |
| Anti-La+ % (n) | 49 (27) | 27 (4) | P=0.0565 |
| ESSPRI median [IQR] | 5 [3–7] | 4 [2– 6] | P=0.3382 |
| ESSDAI median [IQR] | 2 [0– 4] | 2 [1–4] | P=0.8884 |
| Maximum ESSDAI [IQR] | 4 [2–6] | 3 [2–6] | P=0.9519 |
| SSDDI median [IQR] | 1 [1–2] | 1 [0–2] | P=0.1992 |
| Global BILAG median [IQR] | 0 [0–2] | ||
| Treatment | |||
| Hydroxychloroquine (%) | 65 | 40 | P=0.0775 |
| Methotrexate (%) | 5 | 33 | P=**0.0092 |
Unpaired T test performed; **p<0.01, n = total number, % percentage, IQR = interquartile range, ethnicity: C = Caucasian, A = Asian, MN = African Caribbean, O = Chinese, anti-Ro = anti-Sjögren's-syndrome-related antigen A, anti-La = anti-Sjögren's-syndrome-related antigen B.